Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FXR 450 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Arm 1: FXR 450 |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| FXR 450 | DRUG | capsule, single oral doses from 10 mg to 450 mg |
| placebo | DRUG | capsule similar to active drug |
Inclusion Criteria: * Men or women of nonchildbearing potential (WONCBP) aged 18 to 50 years inclusive at screening. * Healthy as determined by the investigator on the basis of screening evaluations. * Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to...
FXR 450 is an investigational small molecule being developed by Pfizer, Inc. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers to evaluate its safety, as part of a completed clinical trial.
FXR 450 is being studied for use in healthy subjects. The completed Phase 1 trial focused on evaluating the safety of FXR-450 in healthy volunteers. Its potential therapeutic application has not been specified beyond this initial safety assessment.
FXR 450 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company conducted a Phase 1 clinical trial to evaluate the safety of the drug in healthy subjects.
FXR 450 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. A Phase 1 trial assessing its safety in healthy subjects has been completed.
FXR 450 has one completed clinical trial, identified as NCT00499629, titled "Study Evaluating the Safety of FXR-450 in Healthy Subjects." This Phase 1 trial enrolled 64 participants in the United States and was placebo-controlled, randomized, and double-blind.
Yes, FXR 450 is the same as FXR-450. The clinical trial NCT00499629 uses the name FXR-450, and both names refer to the same investigational drug being developed by Pfizer, Inc.